Randomized Comparison of Efficacy and Safety of High-intensity Rosuvastatin/Ezetimibe Combination Versus Treat-to-target Rosuvastatin Monotherapy for Patients With Peripheral Artery or Polyvascular Disease (CARE-PVD Trial)

NCT06231966 NA RECRUITING

Patients with atherosclerotic peripheral artery disease often have combined coronary artery disease or cerebral artery disease and show high rates of cardiovascular mortality and morbidities. Therefore, secondary prevention for these patients is of great clinical importance. Currently, Korean, US, and European guidelines recommend different LDL cholesterol target goals in patients with peripheral artery disease. In recent clinical trials, combination therapy of statin plus ezetimibe demonstrated improved cardiovascular outcomes compared with statin monotherapy. Thus, the purpose of the CARE-PVD study is to investigate whether the combination therapy of high intensity rosuvastatin 20 mg plus ezetimibe 10 mg can improve cardiovascular outcomes in patient with peripheral artery disease or polyvascular artery disease in comparison with rosuvastatin treat-to-target (LDL cholesterol \<70 mg/dL) monotherapy.

Details

Lead sponsor	Yonsei University
Phase	NA
Status	RECRUITING
Enrolment	2462
Start date	Mon Apr 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun May 06 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Peripheral Artery Disease
• Polyvascular Disease

Interventions

• Combination therapy of high-intensity dose rosuvastatin and ezetimibe
• Rosuvastatin monotherapy for treat-to-target

Countries

South Korea